Telomir Pharmaceuticals I... (TELO)
NASDAQ: TELO
· Real-Time Price · USD
1.18
-0.02 (-1.67%)
At close: Sep 03, 2025, 3:59 PM
1.16
-1.69%
After-hours: Sep 03, 2025, 05:09 PM EDT
Telomir Pharmaceuticals Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | 18.79M | 18.79M | 18.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 15.4M | 15.4M | 15.4M | 6.01M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 3.39M | 3.39M | 3.39M | -6.01M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -16.17M | -12.57M | -12.3M | -17.96M | -12.91M | -12.86M | -11.43M | -3.35M | -2.63M | -1.27M | -854.15K | -367.05K | -133.55K | -63.49K |
Interest Income | 31.82K | 55.95K | 48K | 40.94K | 25.49K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -16.14M | -12.52M | -16.59M | -23.02M | -18.74M | -18.84M | -13.07M | -4.23M | -2.75M | -1.27M | -854.15K | -367.05K | -133.55K | -63.49K |
Net Income | -16.14M | -12.52M | -16.59M | -23.02M | -18.74M | -18.84M | -13.07M | -4.23M | -2.75M | -1.27M | -854.15K | -367.05K | -133.55K | -63.49K |
Selling & General & Admin | 14.89M | 10.75M | 9.64M | 7.4M | 2.12M | 1.3M | 600.19K | 214.69K | 116.25K | 59.89K | 20.94K | 11.15K | 7.4K | 3.65K |
Research & Development | 1.28M | 1.83M | 2.3M | 2.23M | 1.87M | 1.94M | 1.57M | 1.85M | 1.82M | 1.21M | 833.21K | 355.9K | 126.15K | 59.84K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 16.17M | 12.57M | 12.3M | 10.48M | 5.42M | 5.38M | 3.94M | 3.35M | 2.63M | 1.27M | 854.15K | 367.05K | 133.55K | 63.49K |
Interest Expense | 1.34K | n/a | 4.34M | 5.1M | 5.86M | 5.98M | 1.64M | 881.23K | 124.05K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 16.17M | 12.57M | 12.3M | 10.48M | 5.42M | 5.38M | 3.94M | 3.35M | 2.63M | 1.27M | 854.15K | 367.05K | 133.55K | 63.49K |
Income Tax Expense | n/a | n/a | n/a | -1.08M | -1.08M | -1.08M | -1.08M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 30.01M | 29.76M | 29.54M | 29.61M | 29.61M | 27.77M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M |
Shares Outstanding (Diluted) | 30.01M | 29.76M | 29.54M | 29.61M | 29.61M | 27.77M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M |
EPS (Basic) | -0.54 | -0.42 | -0.58 | -0.8 | -0.66 | -0.66 | -0.45 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | -0.00 | -0.00 |
EPS (Diluted) | -0.54 | -0.42 | -0.58 | -0.8 | -0.66 | -0.66 | -0.45 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | -0.00 | -0.00 |
EBITDA | -16.15M | -12.53M | -12.25M | -17.92M | -12.88M | -12.86M | -10.95M | -2.38M | -1.43M | -70.06K | -133.55K | -133.55K | -133.55K | -63.49K |
EBIT | -16.15M | -12.53M | -12.25M | -17.92M | -12.88M | -12.86M | -11.43M | -3.35M | -2.63M | -1.27M | -854.15K | -367.05K | -133.55K | -63.49K |
Depreciation & Amortization | 246.23K | 271.72K | 2.00 | 3.04M | 3.97M | 5.38M | 3.94M | 3.35M | 2.63M | 1.2M | 720.59K | 233.5K | n/a | n/a |